http://rdf.ncbi.nlm.nih.gov/pubchem/reference/9994372

Outgoing Links

Predicate Object
contentType Journal Article
issn 1742-6405
issueIdentifier 1
pageRange 24-
publicationName AIDS Research and Therapy
startingPage 24
hasFundingAgency http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_06aba5a94448c92faf09747c7e7c67bd
isSupportedBy http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_3ed33d113f87e038dede2bc995e6723f
http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_025f7d23bf8b5419f82b04b2ee9a4f60
bibliographicCitation Togun T, Peterson I, Jaffar S, Oko F, Okomo U, Peterson K, Jaye A. Pre-treatment mortality and loss-to-follow-up in HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients eligible for antiretroviral therapy in The Gambia, West Africa. AIDS Research and Therapy. 2011 Jul 20;8(1):24. doi: 10.1186/1742-6405-8-24.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ea10f46d55bfdc46a6a34f723441680b
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d1fb4c437f78c598f246a5b1f1035466
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-8477-4462
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_98a3d3655b81bdde484113e98e2cc78c
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-9923-1196
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3064298a4718edd7b73d1ed211fd5833
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_af1363b50493419633c123a8dccabc93
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4699390fcde99ecab700da820dd2ab19
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-9615-1588
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_34ad47ac25a601853ad5d761b375925c
date 2011-07-20^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://pubmed.ncbi.nlm.nih.gov/PMC3152879
https://doi.org/10.1186/1742-6405-8-24
https://pubmed.ncbi.nlm.nih.gov/21774813
isPartOf http://rdf.ncbi.nlm.nih.gov/pubchem/journal/32355
https://portal.issn.org/resource/ISSN/1742-6405
language English
source https://scigraph.springernature.com/
https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/
title Pre-treatment mortality and loss-to-follow-up in HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients eligible for antiretroviral therapy in The Gambia, West Africa
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9765
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_68000b5f90a1d5b5b1a93dbb8aa92d3e

Showing number of triples: 1 to 33 of 33.